MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination.

Animals Antibodies, Neutralizing / blood Antibodies, Viral / blood COVID-19 / prevention & control COVID-19 Vaccines / immunology Chlorocebus aethiops Cytomegalovirus / immunology Dogs Female HEK293 Cells Hemagglutinin Glycoproteins, Influenza Virus / immunology Humans Immunity, Cellular Immunity, Humoral Influenza A virus / immunology Influenza Vaccines / immunology Madin Darby Canine Kidney Cells Mice Mice, Inbred BALB C Mice, Inbred C57BL Orthomyxoviridae Infections / prevention & control SARS-CoV-2 / immunology Spike Glycoprotein, Coronavirus / immunology Vaccination / methods Vero Cells

Cytomegalovirus Influenza SARS-CoV-2 Vaccine vector humoral imunity

Journal

Cellular & molecular immunology

ISSN: 2042-0226

Titre abrégé: Cell Mol Immunol

Pays: China

ID NLM: 101242872

Informations de publication

Date de publication:
02 2022

Historique:

received: 27 05 2021

accepted: 25 11 2021

pubmed: 8 1 2022

medline: 11 2 2022

entrez: 7 1 2022

Statut: ppublish

Résumé

Global pandemics caused by influenza or coronaviruses cause severe disruptions to public health and lead to high morbidity and mortality. There remains a medical need for vaccines against these pathogens. CMV (cytomegalovirus) is a β-herpesvirus that induces uniquely robust immune responses in which remarkably large populations of antigen-specific CD8

Identifiants

DOI: 10.1038/s41423-021-00814-5 PMID: 34992275 PMC: PMC8739032

pubmed: 34992275

doi: 10.1038/s41423-021-00814-5

pii: 10.1038/s41423-021-00814-5

pmc: PMC8739032

doi:

Substances chimiques

Antibodies, Neutralizing 0

Antibodies, Viral 0

COVID-19 Vaccines 0

Hemagglutinin Glycoproteins, Influenza Virus 0

Influenza Vaccines 0

Spike Glycoprotein, Coronavirus 0

hemagglutinin, human influenza A virus 0

spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

234-244

Subventions

Organisme : Helmholtz Association

ID : PIE-0008

Informations de copyright

Références

Chen JR, Ma C, Wong CH. Vaccine design of hemagglutinin glycoprotein against influenza. Trends Biotechnol. 2011;29:426–34.

pubmed: 21640418 doi: 10.1016/j.tibtech.2011.04.007

Sriwilaijaroen N, Suzuki Y. Molecular basis of the structure and function of H1 hemagglutinin of influenza virus. Proc Jpn Acad Ser B, Phys Biol Sci. 2012;88:226–49.

doi: 10.2183/pjab.88.226

Cheng YW, Chao TL, Li CL, Chiu MF, Kao HC, Wang SH, et al. Furin inhibitors block SARS-COV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep. 2020;13:108254.

Hoffmann M, Kleine-Weber H, Pohlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78:779–84. e5

pubmed: 32362314 pmcid: 7194065 doi: 10.1016/j.molcel.2020.04.022

Zhao P, Praissman JL, Grant OC, Cai Y, Xiao T, Rosenbalm KE, et al. Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor. Cell Host Microbe. 2020;28:586–601. e6

pubmed: 32841605 pmcid: 7443692 doi: 10.1016/j.chom.2020.08.004

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80. e8

pubmed: 32142651 pmcid: 7102627 doi: 10.1016/j.cell.2020.02.052

WHO. Draft landscape of COVID-19 candidate vaccines. World Health Organization 2020.

Krammer F SARS-CoV-2 vaccines in development. Nature. 2020;586:516–27.

Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature. 2020;586:594–9.

pubmed: 32998157 doi: 10.1038/s41586-020-2814-7

Mahase E. Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week. BMJ. 2020;371:m4714.

pubmed: 33268330 doi: 10.1136/bmj.m4714

WHO. WHO regional office for Europe. Seasonal influenza 2021.

CDC. CDC seasonal Flu Vaccine Effectiveness studies. Centers for Disease Control and Prevention 2021.

Dawood FS, Chung JR, Kim SS, Zimmerman RK, Nowalk MP, Jackson ML, et al. Interim estimates of 2019-20 seasonal influenza vaccine effectiveness - United States, February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:177–82.

pubmed: 32078591 pmcid: 7043386 doi: 10.15585/mmwr.mm6907a1

Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33:492–503.

pubmed: 21029960 pmcid: 3420356 doi: 10.1016/j.immuni.2010.10.002

Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines. 2014;2:624–41.

pubmed: 26344749 pmcid: 4494222 doi: 10.3390/vaccines2030624

Lauer KB, Borrow R, Blanchard TJ Multivalent and multipathogen viral vector vaccines. Clin Vaccine Immunol. 2017;24:e00298–16.

Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis. 2012;55:19–25.

pubmed: 22441650 pmcid: 3369564 doi: 10.1093/cid/cis327

Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011;473:523–7.

pubmed: 21562493 pmcid: 3102768 doi: 10.1038/nature10003

Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, Houser KV, et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PloS One. 2010;5:e13162.

pubmed: 20976273 pmcid: 2953831 doi: 10.1371/journal.pone.0013162

Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med. 2009;15:293–9.

pubmed: 19219024 pmcid: 2720091 doi: 10.1038/nm.1935

Marzi A, Murphy AA, Feldmann F, Parkins CJ, Haddock E, Hanley PW, et al. Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. Sci Rep. 2016;6:21674.

pubmed: 26876974 pmcid: 4753684 doi: 10.1038/srep21674

Alharbi NK, Padron-Regalado E, Thompson CP, Kupke A, Wells D, Sloan MA, et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017;35:3780–8.

pubmed: 28579232 pmcid: 5516308 doi: 10.1016/j.vaccine.2017.05.032

Koch T, Dahlke C, Fathi A, Kupke A, Krahling V, Okba NMA, et al. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect Dis. 2020;20:827–38.

pubmed: 32325037 pmcid: 7172913 doi: 10.1016/S1473-3099(20)30248-6

Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, et al. Protective efficacy of recombinant modified vaccinia virus ankara delivering middle east respiratory syndrome coronavirus spike glycoprotein. J Virol. 2015;89:8651–6.

pubmed: 26018172 pmcid: 4524222 doi: 10.1128/JVI.00614-15

Kim MH, Kim HJ, Chang J. Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus. PloS One. 2019;14:e0220196.

pubmed: 31329652 pmcid: 6645677 doi: 10.1371/journal.pone.0220196

Karrer U, Sierro S, Wagner M, Oxenius A, Hengel H, Koszinowski UH, et al. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol. 2003;170:2022–9.

pubmed: 12574372 doi: 10.4049/jimmunol.170.4.2022

Munks MW, Cho KS, Pinto AK, Sierro S, Klenerman P, Hill AB. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol. 2006;177:450–8.

pubmed: 16785542 doi: 10.4049/jimmunol.177.1.450

Karrer U, Wagner M, Sierro S, Oxenius A, Hengel H, Dumrese T, et al. Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J Virol. 2004;78:2255–64.

pubmed: 14963122 pmcid: 369208 doi: 10.1128/JVI.78.5.2255-2264.2004

Holtappels R, Pahl-Seibert MF, Thomas D, Reddehase MJ. Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs. J Virol. 2000;74:11495–503.

pubmed: 11090146 pmcid: 112429 doi: 10.1128/JVI.74.24.11495-11503.2000

Holtappels R, Thomas D, Podlech J, Reddehase MJ. Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype. J Virol. 2002;76:151–64.

pubmed: 11739681 pmcid: 135724 doi: 10.1128/JVI.76.1.151-164.2002

Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673–85.

pubmed: 16147978 pmcid: 2212883 doi: 10.1084/jem.20050882

Cicin-Sain L, Sylwester AW, Hagen SI, Siess DC, Currier N, Legasse AW, et al. Cytomegalovirus-specific T cell immunity is maintained in immunosenescent rhesus macaques. J Immunol. 2011;187:1722–32.

pubmed: 21765018 doi: 10.4049/jimmunol.1100560

Borkner L, Sitnik KM, Dekhtiarenko I, Pulm AK, Tao R, Drexler I, et al. Immune protection by a cytomegalovirus vaccine vector expressing a single low-avidity epitope. J Immunol. 2017;199:1737–47.

pubmed: 28768725 doi: 10.4049/jimmunol.1602115

Dekhtiarenko I, Ratts RB, Blatnik R, Lee LN, Fischer S, Borkner L, et al. Peptide processing is critical for T-cell memory inflation and may be optimized to improve immune protection by CMV-based vaccine vectors. PLoS Pathog. 2016;12:e1006072.

pubmed: 27977791 pmcid: 5158087 doi: 10.1371/journal.ppat.1006072

Tsuda Y, Caposio P, Parkins CJ, Botto S, Messaoudi I, Cicin-Sain L, et al. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus. PLoS Negl Tropical Dis. 2011;5:e1275.

doi: 10.1371/journal.pntd.0001275

Tsuda Y, Parkins CJ, Caposio P, Feldmann F, Botto S, Ball S, et al. A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose. Vaccine. 2015;33:2261–6.

pubmed: 25820063 pmcid: 4402448 doi: 10.1016/j.vaccine.2015.03.029

Zheng X, Oduro JD, Boehme JD, Borkner L, Ebensen T, Heise U, et al. Mucosal CD8+ T cell responses induced by an MCMV based vaccine vector confer protection against influenza challenge. PLoS Pathog. 2019;15:e1008036.

pubmed: 31525249 pmcid: 6763260 doi: 10.1371/journal.ppat.1008036

Hirsl L, Brizic I, Jenus T, Juranic Lisnic V, Reichel JJ, Jurkovic S, et al. Murine CMV expressing the high affinity NKG2D ligand MULT-1: a model for the development of cytomegalovirus-based vaccines. Front Immunol. 2018;9:991.

pubmed: 29867968 pmcid: 5949336 doi: 10.3389/fimmu.2018.00991

Slavuljica I, Busche A, Babic M, Mitrovic M, Gasparovic I, Cekinovic D, et al. Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J Clin Invest. 2010;120:4532–45.

pubmed: 21099111 pmcid: 2993599 doi: 10.1172/JCI43961

Snyder CM, Allan JE, Bonnett EL, Doom CM, Hill AB. Cross-presentation of a spread-defective MCMV is sufficient to prime the majority of virus-specific CD8+ T cells. PloS One. 2010;5:e9681.

pubmed: 20300633 pmcid: 2837378 doi: 10.1371/journal.pone.0009681

Cicin-Sain L, Bubic I, Schnee M, Ruzsics Z, Mohr C, Jonjic S, et al. Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J Virol. 2007;81:13825–34.

pubmed: 17913824 pmcid: 2168857 doi: 10.1128/JVI.01911-07

Mohr CA, Arapovic J, Mühlbach H, Panzer M, Weyn A, Dölken L, et al. A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination. J Virol. 2010;84:7730–42.

pubmed: 20463067 pmcid: 2897632 doi: 10.1128/JVI.02696-09

Tamura M, Kuwano K, Kurane I, Ennis FA. Definition of amino acid residues on the epitope responsible for recognition by influenza A virus H1-specific, H2-specific, and H1- and H2-cross-reactive murine cytotoxic T-lymphocyte clones. J Virol. 1998;72:9404–6.

pubmed: 9765498 pmcid: 110370 doi: 10.1128/JVI.72.11.9404-9406.1998

Morabito KM, Ruckwardt TR, Redwood AJ, Moin SM, Price DA, Graham BS. Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. Mucosal Immunol. 2017;10:545–54.

pubmed: 27220815 doi: 10.1038/mi.2016.48

Jordan S, Krause J, Prager A, Mitrovic M, Jonjic S, Koszinowski U, et al. Virus progeny of murine cytomegalovirus bacterial artificial chromosome pSM3fr show reduced growth in salivary Glands due to a fixed mutation of MCK-2. J Virol, 2011;85:10346–53. https://doi.org/10.1128/JVI.00545-11 .

pubmed: 21813614 pmcid: 3196435 doi: 10.1128/JVI.00545-11

Chaudhry MZ, Messerle M, Cicin-Sain L. Construction of human cytomegalovirus mutants with markerless BAC mutagenesis. Methods Mol Biol. 2021;2244:133–58.

pubmed: 33555586 doi: 10.1007/978-1-0716-1111-1_8

Dag F, Dolken L, Holzki J, Drabig A, Weingartner A, Schwerk J, et al. Reversible silencing of cytomegalovirus genomes by type I interferon governs virus latency. PLoS Pathog. 2014;10:e1003962.

pubmed: 24586165 pmcid: 3930589 doi: 10.1371/journal.ppat.1003962

Chaudhry MZ, Eschke K, Grashoff M, Abassi L, Kim Y, Brunotte L, et al. SARS-CoV-2 quasispecies mediate rapid virus evolution and adaptation. bioRxiv. 2020:2020.08.10.241414.

Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, et al. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. 2020:2020.06.05.135921.

Welten SPM, Redeker A, Toes REM, Arens R. Viral persistence induces antibody inflation without altering antibody avidity. J Virol. 2016;90:4402–11.

pubmed: 26889035 pmcid: 4836336 doi: 10.1128/JVI.03177-15

Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nostbakken JK, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine. 2010;29:266–73.

pubmed: 21034828 doi: 10.1016/j.vaccine.2010.10.038

Kleine-Weber H, Elzayat MT, Wang L, Graham BS, Müller MA, Drosten C, et al. Mutations in the spike protein of middle east respiratory syndrome coronavirus transmitted in korea increase resistance to antibody-mediated neutralization. J Virol. 2019;93:e01381–18.

Hoffmann M, Arora P, Groß R, Seidel A, Hörnich B, Hahn A, et al. SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination. 2021:2021.02.11.430787.

Berger Rentsch M, Zimmer G. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PloS One. 2011;6:e25858.

pubmed: 21998709 pmcid: 3187809 doi: 10.1371/journal.pone.0025858

Blazejewska P, Koscinski L, Viegas N, Anhlan D, Ludwig S, Schughart K. Pathogenicity of different PR8 influenza A virus variants in mice is determined by both viral and host factors. Virology. 2011;412:36–45.

pubmed: 21256531 doi: 10.1016/j.virol.2010.12.047

Bubić I, Wagner M, Krmpotić A, Saulig T, Kim S, Yokoyama WM, et al. Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol. 2004;78:7536–44.

pubmed: 15220428 pmcid: 434107 doi: 10.1128/JVI.78.14.7536-7544.2004

Cardin RD, Abenes GB, Stoddart CA, Mocarski ES. Murine cytomegalovirus IE2, an activator of gene expression, is dispensable for growth and latency in mice. Virology. 1995;209:236–41.

pubmed: 7747475 doi: 10.1006/viro.1995.1249

Hassert M, Geerling E, Stone ET, Steffen TL, Feldman MS, Dickson AL, et al. mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. PLoS Pathog. 2020;16:e1009163.

pubmed: 33326500 pmcid: 7773324 doi: 10.1371/journal.ppat.1009163

Capel PJ, Gerlag PG, Hagemann JF, Koene RA. The effect of 2-mercaptoethanol on IgM and IgG antibody activity. J Immunol Methods. 1980;36:77–80.

pubmed: 7204997 doi: 10.1016/0022-1759(80)90096-4

Suwannalai P, Scherer HU, van der Woude D, Ioan-Facsinay A, Jol-van der Zijde CM, van Tol MJ, et al. Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. Ann Rheum Dis 2011;70:373–9.

pubmed: 21068094 doi: 10.1136/ard.2010.135509

Ynga-Durand MA, Dekhtiarenko I, Cicin-Sain L Vaccine Vectors Harnessing the Power of Cytomegaloviruses. Vaccines. 2019;7:152.

Murphy K, Travers P, Walport M, Janeway C Janeway’s immunobiology. New York: Garland Science; 2008.

Bongard N, Le-Trilling VTK, Malyshkina A, Rückborn M, Wohlgemuth K, Wensing I, et al. Immunization with a murine cytomegalovirus based vector encoding retrovirus envelope confers strong protection from Friend retrovirus challenge infection. PLoS Pathog. 2019;15:e1008043.

pubmed: 31568492 pmcid: 6786657 doi: 10.1371/journal.ppat.1008043

Trsan T, Busche A, Abram M, Wensveen FM, Lemmermann NA, Arapovic M, et al. Superior induction and maintenance of protective CD8 T cells in mice infected with mouse cytomegalovirus vector expressing RAE-1gamma. Proc Natl Acad Sci USA. 2013;110:16550–5.

pubmed: 24052528 pmcid: 3799388 doi: 10.1073/pnas.1310215110

Slavuljica I, Krmpotic A, Jonjic S. Manipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response. Front Immunol. 2011;2:85.

pubmed: 22566874 pmcid: 3342069

Klyushnenkova EN, Kouiavskaia DV, Parkins CJ, Caposio P, Botto S, Alexander RB. et al. A cytomegalovirus-basedvaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumorgrowth in a murine model of prostate cancer. J Immunother. 2012;35:390–9.

pubmed: 22576344 pmcid: 3366429 doi: 10.1097/CJI.0b013e3182585d50

Grzimek NK, Dreis D, Schmalz S, Reddehase MJ. Random, asynchronous, and asymmetric transcriptional activity of enhancer-flanking major immediate-early genes ie1/3 and ie2 during murine cytomegalovirus latency in the lungs. J Virol. 2001;75:2692–705.

pubmed: 11222693 pmcid: 115894 doi: 10.1128/JVI.75.6.2692-2705.2001

Seckert CK, Griessl M, Buttner JK, Scheller S, Simon CO, Kropp KA, et al. Viral latency drives ‘memory inflation’: a unifying hypothesis linking two hallmarks of cytomegalovirus infection. Med Microbiol Immunol. 2012;201:551–66.

pubmed: 22991040 doi: 10.1007/s00430-012-0273-y

Hansen SG, Marshall EE, Malouli D, Ventura AB, Hughes CM, Ainslie E, et al. A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge. Sci Transl Med. 2019;11:eaaw2607.